NeoStem announces plans to price public offering of common stock

Proceeds will fund development of cell therapeutic product candidates

By Toni Weeks

San Luis Obispo, Calif., Oct. 3 - NeoStem, Inc. said it will price a public sale of common stock.

Aegis Capital Corp. is the bookrunning manager.

Proceeds will be used for working capital, including research and development of AMR-001 and other cell therapeutic product candidates, expansion of business units, strategic transactions and other general corporate purposes.

The New York-based company collects, processes and stores adult stem cells for autologous use in the treatment of cardiac disease, autoimmune disorders and other conditions.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.